lupus

The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) Saphnelo (anifrolumab-fnia) for adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. SLE is an autoimmune disease in which the immune system attacks healthy tissue in...

Shares of small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) are on a tear after the company reported positive clinical readout for its lead asset voclosporin in treating lupus nephritis, an autoimmune disorder. Aurinia has a single-product pipeline. Voclosporin is being evaluated for...

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s Voclosporin is about to begin Phase 3 trials for first-line treatment of lupus nephritis. The company could be an “ideal acquisition candidate once Phase 3 kicks off,” Mackie Research Capital’s André Uddin said in a report. Uddin...